Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Penel

Showing results (91-100 of 350) with videos related to

Pageof 35
Sort By:
Investigational New Drugs|September 18, 2009
Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patientsTanguy Leroy, Véronique Christophe, Nicolas Penel, et al.
Contemporary Clinical Trials|September 16, 2010
Participation in randomised clinical trials is linked to emotion regulation strategiesTanguy Leroy, Véronique Christophe, Nicolas Penel, et al.
Investigational New Drugs|May 12, 2009
Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patientsAntoine Hollebecque, Antoine Adenis, Sophie Taieb, et al.
Plos One|January 10, 2013
Predictive value of clinical judgment of tumour progression in phase II trialsNuria Kotecki, Nicolas Penel, Antoine Adenis, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Regorafenib use as a possible cause of intestinal perforationAntoine Adenis, Nuria Kotecki, Gauthier Decanter, et al.
Chemotherapy|June 14, 2022
Paraneoplastic Demyelinating Inflammatory Neuropathy Revealing Metastatic Seminoma: A Case ReportFrançois Cherifi, Olivier Dereeper, Alexandra Forestier, et al.
Investigational New Drugs|May 8, 2010
Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapyAmélie Lansiaux, Sophie Salingue, Amélie Dewitte, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2022
The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment studyMarion Panhaleux, David Launay, Nicolas Penel, et al.
Acta Oncologica (Stockholm, Sweden)|May 14, 2020
Maintenance therapy and drug holiday in sarcoma patients: systematic reviewLoïc Lebellec, Anne-Sophie Defachelles, Pierre-Yves Cren, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2021
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS TrialSophie Marguet, Antoine Adenis, Stéphanie Delaine-Clisant, et al.
Pageof 35

Showing results (91-100 of 350) with videos related to

Sort By:
Pageof 35
Investigational New Drugs|September 18, 2009
Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patientsTanguy Leroy, Véronique Christophe, Nicolas Penel, et al.
Contemporary Clinical Trials|September 16, 2010
Participation in randomised clinical trials is linked to emotion regulation strategiesTanguy Leroy, Véronique Christophe, Nicolas Penel, et al.
Investigational New Drugs|May 12, 2009
Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patientsAntoine Hollebecque, Antoine Adenis, Sophie Taieb, et al.
Plos One|January 10, 2013
Predictive value of clinical judgment of tumour progression in phase II trialsNuria Kotecki, Nicolas Penel, Antoine Adenis, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Regorafenib use as a possible cause of intestinal perforationAntoine Adenis, Nuria Kotecki, Gauthier Decanter, et al.
Chemotherapy|June 14, 2022
Paraneoplastic Demyelinating Inflammatory Neuropathy Revealing Metastatic Seminoma: A Case ReportFrançois Cherifi, Olivier Dereeper, Alexandra Forestier, et al.
Investigational New Drugs|May 8, 2010
Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapyAmélie Lansiaux, Sophie Salingue, Amélie Dewitte, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2022
The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment studyMarion Panhaleux, David Launay, Nicolas Penel, et al.
Acta Oncologica (Stockholm, Sweden)|May 14, 2020
Maintenance therapy and drug holiday in sarcoma patients: systematic reviewLoïc Lebellec, Anne-Sophie Defachelles, Pierre-Yves Cren, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2021
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS TrialSophie Marguet, Antoine Adenis, Stéphanie Delaine-Clisant, et al.
Pageof 35